A Druggable G Protein Checkpoint in Cholesterol Efflux

20260 citationsJournal Articlegreen Open Access

Authors

Gajanan D. Katkar · University of California San Diego

Mahitha Sree Anandachar · University of California San Diego

Celia R. Espinoza · University of California San Diego

Megan L. Estanol · University of California San Diego

Caroline Biggs · University of California San Diego

Michelle Nacayama · University of California San Diego

Shu-Tsing Hsu

Abstract

Statins slow but rarely reverse plaque burden, leaving residual risk driven by LAM dysfunctionGIV (CCDC88A) non-canonically modulates Gαi to suppress macrophage cholesterol effluxGIV loss or inhibition restores ABCA1 activity via transcriptional and post-translational controlBlocking the GIV●Gαi checkpoint defats LAMs, regresses plaques, and relieves systemic lipid overloadIdentifies a druggable node that redefines RCT restoration as a therapeutic paradigm in immunometabolic disease.

Topics & Keywords

Cholesterol and Lipid Metabolism Immune cells in cancer Cancer, Lipids, and Metabolism

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: bioRxiv (Cold Spring Harbor Laboratory)

DOI: 10.64898/2026.02.15.705962

Field-Weighted Citation Impact: 0.00